The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study.

The impact of the change in the neutrophil-to-lymphocyte ratio (NLR) during neoadjuvant chemotherapy (NAC) on outcomes in patients with muscle-invasive bladder cancer (MIBC) is poorly understood.

To evaluate the prognostic impact of the change in NLR during NAC for patients with MIBC.

Patients referred to academic, community, and quaternary referral centres in Alberta, Canada from 2005 to 2015, Ontario, Canada from 2005 to 2013, and Southampton, UK from 2004 to 2010 were evaluated. 376 eligible patients were treated with NAC for clinical T2-4aN0M0 disease, and 296 were evaluable for the change in NLR. A high NLR was defined as being an NLR > 3. Relationships between the change in NLR from baseline to mid-NAC (pre-cycle 3) and outcomes were analyzed using multivariable Cox regression. Kaplan-Meier analysis was used with the log-rank test for group comparisons.

Median follow-up was 22.0 months (95% confidence interval [CI]: 14.9-30.0). Patients with a sustained high NLR had a median disease-free survival (DFS) of 12.6 months, compared to 34.8 months for those with a sustained low NLR (log-rank test p = 0.0025; hazard ratio [HR] 0.61 [95% CI: 0.44-0.84]). Median overall survival (OS) was 19.4 months for patients with a sustained high NLR, compared to 44.0 months for patients with a sustained low NLR (log-rank test p = 0.0011; HR 0.54 [95% CI: 0.38-0.77]).

A sustained high NLR from baseline to mid-NAC is an independent prognostic factor for patients with MIBC.

Bladder cancer (Amsterdam, Netherlands). 2018 Apr 26*** epublish ***

Jeenan Kaiser, Haocheng Li, Scott A North, Raya Leibowitz-Amit, Jo-An Seah, Nisha Morshed, Caroline Chau, Richard Lee-Ying, Daniel Y C Heng, Srikala Sridhar, Simon J Crabb, Nimira S Alimohamed

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, AB, Canada., Cross Cancer Institute, Edmonton, AB, Canada., Sheba Medical Center, Ramat-Gan, Israel., Princess Margaret Cancer Centre, University Health Network, Division of Oncology and Haematology, Toronto, ON, Canada., Cancer Sciences Unit, University of Southampton, Southampton, UK., Princess Margaret Cancer Centre, Toronto, ON, Canada.